marketcaparena
Search

    BLCO

    Bausch & Lomb Corp

    Company overview

    Market capitalization
    $6.05B
    Employees
    13,000
    Latest publication
    2026-09-29
    About Bausch & Lomb Corp

    Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ4 20242024-12-31 · USDQ4 20222022-12-31 · USDQ4 20202020-12-31 · USDQ3 20202020-09-30 · USDQ2 20202020-06-30 · USD
    Total Revenue1,394,000,000USD1,244,000,000USD1,405,000,000USD1,280,000,000USD996,000,000USD944,000,000USD916,000,000USD776,000,000USD
    Cost Of Revenue1,054,000,000USD540,000,000USD589,000,000USD501,000,000USD420,000,000USD370,000,000USD330,000,000USD292,500,000USD
    Gross Profit340,000,000USD704,000,000USD816,000,000USD779,000,000USD576,000,000USD574,000,000USD586,000,000USD483,500,000USD
    Research Development114,000,000USD101,000,000USD94,000,000USD93,000,000USD78,000,000USD77,000,000USD61,000,000USD63,000,000USD
    Selling General Administrative588,000,000USD544,000,000USD564,000,000USD4,000,000USD67,000,000USD46,000,000USD——
    Total Operating Expenses257,000,000USD645,000,000USD658,000,000USD692,000,000USD525,000,000USD491,000,000USD465,000,000USD455,500,000USD
    Operating Income83,000,000USD59,000,000USD158,000,000USD87,000,000USD51,000,000USD83,000,000USD121,000,000USD28,000,000USD
    Total Other Income Expense Net-94,000,000USD-123,000,000USD-145,000,000USD-97,000,000USD-53,000,000USD20,000,000USD9,000,000USD500,000USD
    Interest Income4,000,000USD4,000,000USD3,000,000USD5,000,000USD3,000,000USD———
    Interest Expense93,000,000USD100,000,000USD100,000,000USD98,000,000USD47,000,000USD1,000,000USD——
    Income Before Tax-11,000,000USD-64,000,000USD13,000,000USD-10,000,000USD-2,000,000USD103,000,000USD130,000,000USD28,500,000USD
    Income Tax Expense-1,000,000USD6,000,000USD71,000,000USD-8,000,000USD-2,000,000USD311,000,000USD46,000,000USD-25,000,000USD
    Net Income-10,000,000USD-71,000,000USD-58,000,000USD-3,000,000USD-1,000,000USD-209,000,000USD85,000,000USD53,000,000USD
    Minority Interest4,000,000USD-1,000,000USD0USD-1,000,000USD1,000,000USD———
    Net Income Applicable To Common Shares-14,000,000USD———-1,000,000USD———
    Net Interest Income—-93,000,000USD-95,000,000USD-93,000,000USD-44,000,000USD———
    Tax Provision—6,000,000USD71,000,000USD-8,000,000USD-2,000,000USD———
    Net Income From Continuing Ops—-70,000,000USD-58,000,000USD-2,000,000USD0USD———
    Ebit—36,000,000USD113,000,000USD88,000,000USD45,000,000USD90,000,000USD120,000,000USD30,000,000USD
    Ebitda—137,000,000USD212,000,000USD194,000,000USD138,000,000USD196,000,000USD233,000,000USD141,500,000USD
    Depreciation And Amortization—101,000,000USD99,000,000USD106,000,000USD93,000,000USD106,000,000USD113,000,000USD111,500,000USD
    Reconciled Depreciation—101,000,000USD99,000,000USD106,000,000USD93,000,000USD106,000,000USD——
    Selling And Marketing Expenses———528,000,000USD319,000,000USD285,000,000USD——
    Unclassified Operating Expenses———67,000,000USD61,000,000USD83,000,000USD404,000,000USD392,500,000USD
    Non Operating Income Net Other————-6,000,000USD———
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20202020-12-31 · USD
    Total Revenue3,412,000,000USD
    Cost Of Revenue1,285,000,000USD
    Gross Profit2,127,000,000USD
    Research Development281,000,000USD
    Selling General Administrative968,000,000USD
    Selling And Marketing Expenses285,000,000USD
    Unclassified Operating Expenses333,000,000USD
    Total Operating Expenses1,867,000,000USD
    Operating Income260,000,000USD
    Interest Income3,000,000USD
    Interest Expense19,000,000USD
    Net Interest Income3,000,000USD
    Income Before Tax290,000,000USD
    Income Tax Expense307,000,000USD
    Tax Provision307,000,000USD
    Net Income-18,000,000USD
    Net Income From Continuing Ops-17,000,000USD
    Ebit290,000,000USD
    Ebitda732,000,000USD
    Depreciation And Amortization442,000,000USD
    Reconciled Depreciation442,000,000USD
    Total Other Income Expense Net30,000,000USD
    Minority Interest-1,000,000USD
    Net Income Applicable To Common Shares-18,000,000USD
    SourceLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets13,859,000,000USD13,780,000,000USD14,022,000,000USD13,832,000,000USD13,832,000,000USD13,428,000,000USD13,469,000,000USD13,515,000,000USD
    Cash And Equivalents367,000,000USD———————
    Total Current Assets2,922,000,000USD2,776,000,000USD2,977,000,000USD2,855,000,000USD2,846,000,000USD2,694,000,000USD2,788,000,000USD2,828,000,000USD
    Other Current Assets385,000,000USD425,000,000USD397,000,000USD451,000,000USD435,000,000USD454,000,000USD421,000,000USD437,000,000USD
    Other Non Current Assets294,000,000USD———————
    Total Liabilities7,415,000,000USD———————
    Total Current Liabilities1,890,000,000USD1,820,000,000USD1,920,000,000USD1,896,000,000USD1,840,000,000USD1,726,000,000USD1,738,000,000USD1,801,000,000USD
    Other Current Liabilities1,421,000,000USD———————
    Other Non Current Liabilities435,000,000USD———————
    Total Stockholder Equity6,376,000,000USD6,379,000,000USD6,448,000,000USD6,429,000,000USD6,440,000,000USD6,361,000,000USD6,473,000,000USD6,589,000,000USD
    Total Equity Including Noncontrolling Interest6,444,000,000USD———————
    Short Long Term Debt28,000,000USD39,000,000USD39,000,000USD28,000,000USD28,000,000USD40,000,000USD40,000,000USD30,000,000USD
    Long Term Debt5,049,000,000USD5,031,000,000USD5,043,000,000USD4,922,000,000USD4,931,000,000USD4,789,000,000USD4,744,000,000USD4,599,000,000USD
    Inventory999,000,000USD977,000,000USD976,000,000USD1,005,000,000USD1,051,000,000USD1,031,000,000USD1,036,000,000USD1,119,000,000USD
    Property Plant Equipment Net1,799,000,000USD1,794,000,000USD1,762,000,000USD1,711,000,000USD1,680,000,000USD1,581,000,000USD1,485,000,000USD1,481,000,000USD
    Goodwill4,723,000,000USD———————
    Intangible Assets3,169,000,000USD3,226,000,000USD3,281,000,000USD3,328,000,000USD3,361,000,000USD3,427,000,000USD3,494,000,000USD3,384,000,000USD
    Accounts Payable426,000,000USD407,000,000USD388,000,000USD395,000,000USD449,000,000USD427,000,000USD389,000,000USD455,000,000USD
    Common Stock0USD———————
    Retained Earnings-1,016,000,000USD-1,002,000,000USD-931,000,000USD-873,000,000USD-845,000,000USD-783,000,000USD-571,000,000USD-568,000,000USD
    Accumulated Other Comprehensive Income-1,218,000,000USD-1,199,000,000USD-1,184,000,000USD-1,198,000,000USD-1,191,000,000USD-1,304,000,000USD-1,385,000,000USD-1,248,000,000USD
    Total Liab—7,328,000,000USD7,503,000,000USD7,332,000,000USD7,324,000,000USD6,995,000,000USD6,925,000,000USD6,854,000,000USD
    Other Current Liab—1,374,000,000USD1,455,000,000USD1,473,000,000USD1,363,000,000USD1,259,000,000USD1,277,000,000USD1,249,000,000USD
    Capital Stock—0USD0USD0USD0USD0USD0USD0USD
    Good Will—4,737,000,000USD4,758,000,000USD4,657,000,000USD4,667,000,000USD4,567,000,000USD4,523,000,000USD4,581,000,000USD
    Cash—268,000,000USD383,000,000USD310,000,000USD272,000,000USD202,000,000USD305,000,000USD329,000,000USD
    Cash And Short Term Investments—268,000,000USD383,000,000USD310,000,000USD272,000,000USD202,000,000USD305,000,000USD329,000,000USD
    Net Debt—4,802,000,000USD4,987,000,000USD4,640,000,000USD4,687,000,000USD4,627,000,000USD4,631,000,000USD4,300,000,000USD
    Short Term Debt—39,000,000USD77,000,000USD28,000,000USD28,000,000USD40,000,000USD72,000,000USD30,000,000USD
    Short Long Term Debt Total—5,070,000,000USD5,370,000,000USD4,950,000,000USD4,959,000,000USD4,829,000,000USD4,936,000,000USD4,629,000,000USD
    Net Receivables—1,106,000,000USD1,221,000,000USD1,094,000,000USD1,088,000,000USD1,007,000,000USD1,026,000,000USD943,000,000USD
    Common Stock Shares Outstanding—355,200,000shares354,400,000shares354,200,000shares353,700,000shares352,800,000shares351,800,000shares353,900,000shares
    Non Current Assets Total—11,004,000,000USD11,045,000,000USD10,977,000,000USD10,986,000,000USD10,734,000,000USD10,681,000,000USD10,687,000,000USD
    Non Current Liabilities Total—5,508,000,000USD5,583,000,000USD5,436,000,000USD5,484,000,000USD5,269,000,000USD5,187,000,000USD5,053,000,000USD
    Non Current Liabilities Other—458,000,000USD521,000,000USD500,000,000USD539,000,000USD467,000,000USD430,000,000USD442,000,000USD
    Non Currrent Assets Other—302,000,000USD303,000,000USD303,000,000USD298,000,000USD288,000,000USD275,000,000USD291,000,000USD
    Net Working Capital—956,000,000USD1,057,000,000USD959,000,000USD1,006,000,000USD968,000,000USD1,050,000,000USD1,027,000,000USD
    Unclassified Non Current Assets—945,000,000USD941,000,000USD978,000,000USD980,000,000USD871,000,000USD904,000,000USD950,000,000USD
    Unclassified Current Liabilities—-39,000,000USD-39,000,000USD-28,000,000USD-28,000,000USD-40,000,000USD-40,000,000USD37,000,000USD
    Unclassified Equity—8,580,000,000USD8,563,000,000USD8,500,000,000USD8,476,000,000USD8,448,000,000USD8,429,000,000USD8,405,000,000USD
    Property Plant Equipment Gross——3,658,000,000USD———3,169,000,000USD—
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets14,022,000,000USD13,469,000,000USD13,442,000,000USD11,144,000,000USD10,823,000,000USD11,266,000,000USD11,468,000,000USD—
    Intangible Assets3,281,000,000USD3,494,000,000USD3,589,000,000USD2,058,000,000USD2,264,000,000USD2,562,000,000USD2,855,000,000USD—
    Other Current Assets397,000,000USD421,000,000USD505,000,000USD403,000,000USD168,000,000USD155,000,000USD198,000,000USD—
    Total Liab7,503,000,000USD6,925,000,000USD6,522,000,000USD4,043,000,000USD1,421,000,000USD1,278,000,000USD1,436,000,000USD—
    Total Stockholder Equity6,448,000,000USD6,473,000,000USD6,850,000,000USD7,033,000,000USD9,329,000,000USD9,918,000,000USD9,959,000,000USD—
    Other Current Liab1,455,000,000USD1,277,000,000USD1,000,000,000USD928,000,000USD812,000,000USD712,000,000USD719,000,000USD—
    Capital Stock0USD0USD0USD0USD10,364,000,000USD10,807,000,000USD11,005,000,000USD—
    Retained Earnings-931,000,000USD-571,000,000USD-254,000,000USD6,000,000USD0USD———
    Good Will4,758,000,000USD4,523,000,000USD4,575,000,000USD4,507,000,000USD4,586,000,000USD4,685,000,000USD4,554,000,000USD—
    Cash383,000,000USD305,000,000USD334,000,000USD380,000,000USD174,000,000USD238,000,000USD192,000,000USD—
    Cash And Short Term Investments383,000,000USD305,000,000USD334,000,000USD380,000,000USD174,000,000USD238,000,000USD192,000,000USD—
    Total Current Assets2,977,000,000USD2,788,000,000USD2,742,000,000USD2,137,000,000USD1,635,000,000USD1,654,000,000USD1,695,000,000USD—
    Total Current Liabilities1,920,000,000USD1,738,000,000USD1,579,000,000USD1,296,000,000USD1,099,000,000USD909,000,000USD1,035,000,000USD—
    Net Debt4,987,000,000USD4,631,000,000USD4,342,000,000USD2,174,000,000USD-34,000,000USD-137,000,000USD-99,000,000USD—
    Short Term Debt77,000,000USD72,000,000USD57,000,000USD51,000,000USD48,000,000USD18,000,000USD16,000,000USD—
    Short Long Term Debt39,000,000USD40,000,000USD30,000,000USD25,000,000USD28,000,000USD———
    Short Long Term Debt Total5,370,000,000USD4,936,000,000USD4,676,000,000USD2,554,000,000USD140,000,000USD101,000,000USD93,000,000USD—
    Long Term Debt5,043,000,000USD4,744,000,000USD4,532,000,000USD2,411,000,000USD————
    Net Receivables1,221,000,000USD1,026,000,000USD875,000,000USD726,000,000USD721,000,000USD645,000,000USD713,000,000USD—
    Inventory976,000,000USD1,036,000,000USD1,028,000,000USD628,000,000USD572,000,000USD616,000,000USD592,000,000USD—
    Accounts Payable388,000,000USD389,000,000USD522,000,000USD317,000,000USD239,000,000USD178,000,000USD262,000,000USD—
    Property Plant Equipment Net1,762,000,000USD1,485,000,000USD1,504,000,000USD1,419,000,000USD1,225,000,000USD1,264,000,000USD1,090,000,000USD—
    Property Plant Equipment Gross3,658,000,000USD3,169,000,000USD3,020,000,000USD2,815,000,000USD2,549,000,000USD2,427,000,000USD2,125,000,000USD—
    Accumulated Other Comprehensive Income-1,184,000,000USD-1,385,000,000USD-1,245,000,000USD-1,258,000,000USD-1,035,000,000USD-889,000,000USD-1,046,000,000USD—
    Common Stock Shares Outstanding353,800,000shares351,800,000shares350,500,000shares350,000,000shares350,000,000shares350,000,000shares350,000,000shares350,000,000shares
    Non Current Assets Total11,045,000,000USD10,681,000,000USD10,700,000,000USD9,007,000,000USD9,188,000,000USD9,612,000,000USD9,773,000,000USD—
    Non Current Liabilities Total5,583,000,000USD5,187,000,000USD4,943,000,000USD2,747,000,000USD322,000,000USD369,000,000USD401,000,000USD—
    Non Current Liabilities Other521,000,000USD430,000,000USD397,000,000USD329,000,000USD298,000,000USD342,000,000USD363,000,000USD—
    Non Currrent Assets Other303,000,000USD275,000,000USD92,000,000USD84,000,000USD180,000,000USD65,000,000USD82,000,000USD—
    Net Working Capital1,057,000,000USD1,050,000,000USD1,163,000,000USD841,000,000USD536,000,000USD745,000,000USD660,000,000USD—
    Unclassified Non Current Assets941,000,000USD904,000,000USD940,000,000USD—————
    Unclassified Current Liabilities-39,000,000USD-40,000,000USD-657,000,000USD-25,000,000USD-28,000,000USD—38,000,000USD—
    Unclassified Equity8,563,000,000USD8,429,000,000USD8,349,000,000USD8,285,000,000USD-10,364,000,000USD-10,807,000,000USD-11,005,000,000USD—
    Current Deferred Revenue——627,000,000USD—-20,000,000USD-18,000,000USD-16,000,000USD—
    Deferred Long Term Liab———7,000,000USD————
    Other Liab———244,000,000USD230,000,000USD286,000,000USD324,000,000USD—
    Other Assets———1,023,000,000USD1,001,000,000USD1,101,000,000USD1,274,000,000USD—
    Net Tangible Assets———468,000,000USD2,479,000,000USD2,671,000,000USD2,550,000,000USD—
    Unclassified Non Current Liabilities———-244,000,000USD-206,000,000USD-259,000,000USD-286,000,000USD—
    Common Stock————10,364,000,000USD10,807,000,000USD11,005,000,000USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation203,000,000USD
    Stock Based Compensation72,000,000USD
    Other Non Cash Items2,000,000USD
    Change To Account Receivables55,000,000USD
    Change To Inventory-58,000,000USD
    Change To Liabilities1,000,000USD
    Change In Working Capital-27,000,000USD
    Operating Cash Flow185,000,000USD
    Capital Expenditures-171,000,000USD
    Net Investments-54,000,000USD
    Unclassified Investing Cash Flow8,000,000USD
    Investing Cash Flow-217,000,000USD
    Net Debt Issuance46,000,000USD
    Net Common Stock Issuance-27,000,000USD
    Other Financing Activities-7,000,000USD
    Unclassified Financing Cash Flow2,000,000USD
    Financing Cash Flow14,000,000USD
    Effect Of Forex Changes On Cash-1,000,000USD
    Change In Cash-19,000,000USD
    End Cash Flow378,000,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-71,000,000USD-58,000,000USD-28,000,000USD-58,000,000USD-211,000,000USD-2,000,000USD8,000,000USD-148,000,000USD
    Depreciation101,000,000USD99,000,000USD109,000,000USD107,000,000USD106,000,000USD106,000,000USD110,000,000USD110,000,000USD
    Stock Based Compensation34,000,000USD64,000,000USD27,000,000USD30,000,000USD28,000,000USD27,000,000USD24,000,000USD22,000,000USD
    Other Non Cash Items26,000,000USD96,197,758USD25,436,713USD17,000,000USD34,000,000USD45,148,000USD20,000,000USD21,000,000USD
    Change To Account Receivables108,000,000USD-130,034,649USD-14,200,879USD-50,000,000USD46,000,000USD-119,000,000USD58,000,000USD-74,000,000USD
    Change To Inventory-22,000,000USD27,926,296USD20,334,718USD2,000,000USD-12,000,000USD14,000,000USD-48,000,000USD-27,000,000USD
    Change In Working Capital-46,000,000USD-68,267,571USD37,417,170USD48,000,000USD23,000,000USD-182,000,000USD98,000,000USD-14,000,000USD
    Total Cash From Operating Activities32,000,000USD134,337,266USD139,054,302USD35,000,000USD-25,000,000USD22,000,000USD154,000,000USD15,000,000USD
    Capital Expenditures-100,000,000USD-72,540,926USD-74,521,372USD-89,000,000USD-110,000,000USD-92,000,000USD-60,000,000USD-72,000,000USD
    Free Cash Flow-68,000,000USD61,796,340USD64,532,929USD-54,000,000USD-135,000,000USD-70,000,000USD94,000,000USD-57,000,000USD
    Investments0USD-3,000,000USD-61,000,000USD-90,000,000USD-116,000,000USD-185,000,000USD-96,000,000USD-74,000,000USD
    Total Cashflows From Investing Activities-130,000,000USD-184,855,875USD-61,302,291USD-90,000,000USD-116,000,000USD-185,000,000USD-96,000,000USD-74,000,000USD
    Net Borrowings-3,000,000USD117,000,000USD-7,000,000USD111,000,000USD40,000,000USD149,000,000USD-8,000,000USD—
    Total Cash From Financing Activities-20,000,000USD114,798,946USD-12,550,256USD90,000,000USD31,000,000USD146,000,000USD-20,000,000USD40,000,000USD
    Change In Cash-118,000,000USD65,000,000USD60,000,000USD57,000,000USD-101,000,000USD-34,000,000USD48,000,000USD-23,000,000USD
    Begin Period Cash Flow397,000,000USD332,000,000USD272,000,000USD215,000,000USD316,000,000USD350,000,000USD302,000,000USD325,000,000USD
    End Period Cash Flow279,000,000USD397,000,000USD332,000,000USD272,000,000USD215,000,000USD316,000,000USD350,000,000USD302,000,000USD
    Other Cashflows From Investing Activities-30,000,000USD-159,071USD6,073,069USD-1,000,000USD6,000,000USD1,017,000USD7,000,000USD1,000,000USD
    Other Cashflows From Financing Activities-19,000,000USD-697,220USD7,197,671USD-19,000,000USD-9,000,000USD-3,000,000USD-11,000,000USD-3,000,000USD
    Unclassified Operating Cash Flow-12,000,000USD1,407,079USD-31,799,581USD-109,000,000USD-5,000,000USD27,852,000USD-106,000,000USD24,000,000USD
    Unclassified Financing Cash Flow2,000,000USD-1,503,834USD-23,747,927USD—9,000,000USD3,000,000USD—46,000,000USD
    Unclassified Investing Cash Flow—-109,155,878USD68,146,012USD90,000,000USD104,000,000USD90,983,000USD53,000,000USD71,000,000USD
    Sale Purchase Of Stock——11,000,000USD-2,000,000USD-9,000,000USD-3,000,000USD-1,000,000USD-3,000,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income-352,000,000USD-305,000,000USD-248,000,000USD15,000,000USD193,000,000USD-17,000,000USD303,000,000USD719,000,000USD
    Depreciation421,000,000USD436,000,000USD382,000,000USD379,000,000USD415,000,000USD442,000,000USD469,000,000USD495,000,000USD
    Stock Based Compensation149,000,000USD92,000,000USD74,000,000USD62,000,000USD62,000,000USD50,000,000USD50,000,000USD43,000,000USD
    Other Non Cash Items79,000,000USD106,000,000USD72,000,000USD-2,000,000USD59,000,000USD9,000,000USD56,000,000USD28,000,000USD
    Change To Account Receivables-148,000,000USD-227,000,000USD-121,000,000USD-95,000,000USD-107,000,000USD77,000,000USD-21,000,000USD-9,000,000USD
    Change To Inventory38,000,000USD-147,000,000USD-264,000,000USD-106,000,000USD-15,000,000USD-32,000,000USD-91,000,000USD-7,000,000USD
    Change In Working Capital18,000,000USD-87,000,000USD-287,000,000USD-19,000,000USD28,000,000USD-59,000,000USD-40,000,000USD-78,000,000USD
    Total Cash From Operating Activities283,000,000USD232,000,000USD-17,000,000USD345,000,000USD873,000,000USD522,000,000USD799,000,000USD763,000,000USD
    Capital Expenditures-349,000,000USD-291,000,000USD-181,000,000USD-175,000,000USD-193,000,000USD-259,000,000USD-180,000,000USD-101,000,000USD
    Free Cash Flow-66,000,000USD-59,000,000USD-198,000,000USD170,000,000USD680,000,000USD263,000,000USD619,000,000USD662,000,000USD
    Investments-3,000,000USD-412,000,000USD-2,064,000,000USD-40,000,000USD-5,000,000USD3,000,000USD-6,000,000USD-6,000,000USD
    Total Cashflows From Investing Activities-455,000,000USD-412,000,000USD-2,109,000,000USD-215,000,000USD-214,000,000USD-256,000,000USD-186,000,000USD-74,000,000USD
    Net Borrowings261,000,000USD201,000,000USD2,115,000,000USD2,424,000,000USD28,000,000USD28,000,000USD28,000,000USD28,000,000USD
    Total Cash From Financing Activities225,000,000USD178,000,000USD2,078,000,000USD81,000,000USD-712,000,000USD-232,000,000USD-606,000,000USD-665,000,000USD
    Change In Cash81,000,000USD-18,000,000USD-46,000,000USD203,000,000USD-61,000,000USD46,000,000USD4,000,000USD16,000,000USD
    Begin Period Cash Flow316,000,000USD334,000,000USD380,000,000USD177,000,000USD238,000,000USD192,000,000USD188,000,000USD172,000,000USD
    End Period Cash Flow397,000,000USD316,000,000USD334,000,000USD380,000,000USD177,000,000USD238,000,000USD192,000,000USD188,000,000USD
    Other Cashflows From Investing Activities-103,000,000USD-123,000,000USD14,000,000USD-45,000,000USD-16,000,000USD-6,000,000USD-6,000,000USD27,000,000USD
    Other Cashflows From Financing Activities-24,000,000USD-11,000,000USD-37,000,000USD-2,377,000,000USD-740,000,000USD-232,000,000USD-606,000,000USD-665,000,000USD
    Unclassified Operating Cash Flow-32,000,000USD-10,000,000USD-10,000,000USD-90,000,000USD116,000,000USD97,000,000USD-39,000,000USD-444,000,000USD
    Unclassified Financing Cash Flow-12,000,000USD——45,000,000USD—-28,000,000USD-28,000,000USD-28,000,000USD
    Sale Purchase Of Stock—-12,000,000USD-10,000,000USD-11,000,000USD————
    Unclassified Investing Cash Flow—414,000,000USD122,000,000USD45,000,000USD—6,000,000USD6,000,000USD6,000,000USD
    Change To Liabilities———189,000,000USD163,000,000USD-144,000,000USD78,000,000USD-19,000,000USD
    Cash And Cash Equivalents Changes———211,000,000USD————
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30ProductBrandedand Other Generic Products68,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductDevice Products524,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductOther Revenues5,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductOverthe Counter Products497,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductPharmaceutical Products300,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductProduct And Service Other5,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30SegmentPharmaceuticals354,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30SegmentSurgical256,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30SegmentVision Care784,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductBrandedand Other Generic Products49,000,000USD0001860742-26-000062
    Q1 2026Quarterly · 2026-03-31ProductDevice Products480,000,000USD0001860742-26-000062
    Q1 2026Quarterly · 2026-03-31ProductOther Revenues5,000,000USD0001860742-26-000062
    Q1 2026Quarterly · 2026-03-31ProductOverthe Counter Products444,000,000USD0001860742-26-000062
    Q1 2026Quarterly · 2026-03-31ProductPharmaceutical Products266,000,000USD0001860742-26-000062
    Q1 2026Quarterly · 2026-03-31ProductProduct And Service Other5,000,000USD0001860742-26-000062
    Q1 2026Quarterly · 2026-03-31SegmentPharmaceuticals305,000,000USD0001860742-26-000062
    Q1 2026Quarterly · 2026-03-31SegmentSurgical228,000,000USD0001860742-26-000062
    Q1 2026Quarterly · 2026-03-31SegmentVision Care711,000,000USD0001860742-26-000062
    Q4 2025Quarterly · 2025-12-31ProductBrandedand Other Generic Products72,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductDevice Products518,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductOther Revenues7,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductOverthe Counter Products489,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductPharmaceutical Products319,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductProduct And Service Other7,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31SegmentPharmaceuticals378,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31SegmentSurgical249,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31SegmentVision Care778,000,000USDLegacy provider
    FY 2025Yearly · 2025-12-31GeographyCanada135,000,000USD0001860742-26-000007
    FY 2025Yearly · 2025-12-31GeographyChina358,000,000USD0001860742-26-000007
    FY 2025Yearly · 2025-12-31GeographyES101,000,000USD0001860742-26-000007
    FY 2025Yearly · 2025-12-31GeographyFrance246,000,000USD0001860742-26-000007
    FY 2025Yearly · 2025-12-31GeographyGermany164,000,000USD0001860742-26-000007
    FY 2025Yearly · 2025-12-31GeographyItaly102,000,000USD0001860742-26-000007
    FY 2025Yearly · 2025-12-31GeographyJapan186,000,000USD0001860742-26-000007
    FY 2025Yearly · 2025-12-31GeographyMX75,000,000USD0001860742-26-000007
    FY 2025Yearly · 2025-12-31GeographyOther Countries777,000,000USD0001860742-26-000007
    FY 2025Yearly · 2025-12-31GeographyPL75,000,000USD0001860742-26-000007
    FY 2025Yearly · 2025-12-31GeographyRU148,000,000USD0001860742-26-000007
    FY 2025Yearly · 2025-12-31GeographySouth Korea51,000,000USD0001860742-26-000007
    FY 2025Yearly · 2025-12-31GeographyUnited Kingdom137,000,000USD0001860742-26-000007
    FY 2025Yearly · 2025-12-31GeographyUnited Statesand Puerto Rico2,546,000,000USD0001860742-26-000007
    FY 2025Yearly · 2025-12-31ProductBrandedand Other Generic Products243,000,000USD0001860742-26-000007
    FY 2025Yearly · 2025-12-31ProductDevice Products1,922,000,000USD0001860742-26-000007
    FY 2025Yearly · 2025-12-31ProductOther Revenues21,000,000USD0001860742-26-000007
    FY 2025Yearly · 2025-12-31ProductOverthe Counter Products1,834,000,000USD0001860742-26-000007
    FY 2025Yearly · 2025-12-31ProductPharmaceutical Products1,081,000,000USD0001860742-26-000007
    FY 2025Yearly · 2025-12-31ProductProduct And Service Other21,000,000USD0001860742-26-000007
    FY 2025Yearly · 2025-12-31SegmentPharmaceuticals1,284,000,000USD0001860742-26-000007
    FY 2025Yearly · 2025-12-31SegmentSurgical894,000,000USD0001860742-26-000007
    FY 2025Yearly · 2025-12-31SegmentVision Care2,923,000,000USD0001860742-26-000007
    Q3 2025Quarterly · 2025-09-30ProductBrandedand Other Generic Products59,000,000USD0001860742-25-000023
    Q3 2025Quarterly · 2025-09-30ProductDevice Products484,000,000USD0001860742-25-000023
    Q3 2025Quarterly · 2025-09-30ProductOther Revenues4,000,000USD0001860742-25-000023
    Q3 2025Quarterly · 2025-09-30ProductOverthe Counter Products454,000,000USD0001860742-25-000023
    Q3 2025Quarterly · 2025-09-30ProductPharmaceutical Products280,000,000USD0001860742-25-000023
    Q3 2025Quarterly · 2025-09-30ProductProduct And Service Other4,000,000USD0001860742-25-000023
    Q3 2025Quarterly · 2025-09-30SegmentPharmaceuticals330,000,000USD0001860742-25-000023
    Q3 2025Quarterly · 2025-09-30SegmentSurgical215,000,000USD0001860742-25-000023
    Q3 2025Quarterly · 2025-09-30SegmentVision Care736,000,000USD0001860742-25-000023
    Q2 2025Quarterly · 2025-06-30ProductBrandedand Other Generic Products58,000,000USD0001860742-25-000018
    Q2 2025Quarterly · 2025-06-30ProductDevice Products472,000,000USD0001860742-25-000018
    Q2 2025Quarterly · 2025-06-30ProductOther Revenues6,000,000USD0001860742-25-000018
    Q2 2025Quarterly · 2025-06-30ProductOverthe Counter Products482,000,000USD0001860742-25-000018
    Q2 2025Quarterly · 2025-06-30ProductPharmaceutical Products260,000,000USD0001860742-25-000018
    Q2 2025Quarterly · 2025-06-30ProductProduct And Service Other6,000,000USD0001860742-25-000018
    Q2 2025Quarterly · 2025-06-30SegmentPharmaceuticals309,000,000USD0001860742-25-000018
    Q2 2025Quarterly · 2025-06-30SegmentSurgical216,000,000USD0001860742-25-000018
    Q2 2025Quarterly · 2025-06-30SegmentVision Care753,000,000USD0001860742-25-000018
    Q1 2025Quarterly · 2025-03-31ProductBrandedand Other Generic Products54,000,000USD0001860742-26-000062
    Q1 2025Quarterly · 2025-03-31ProductDevice Products448,000,000USD0001860742-26-000062
    Q1 2025Quarterly · 2025-03-31ProductOther Revenues4,000,000USD0001860742-26-000062
    Q1 2025Quarterly · 2025-03-31ProductOverthe Counter Products409,000,000USD0001860742-26-000062
    Q1 2025Quarterly · 2025-03-31ProductPharmaceutical Products222,000,000USD0001860742-26-000062
    Q1 2025Quarterly · 2025-03-31ProductProduct And Service Other4,000,000USD0001860742-26-000062
    Q1 2025Quarterly · 2025-03-31SegmentPharmaceuticals267,000,000USD0001860742-26-000062
    Q1 2025Quarterly · 2025-03-31SegmentSurgical214,000,000USD0001860742-26-000062
    Q1 2025Quarterly · 2025-03-31SegmentVision Care656,000,000USD0001860742-26-000062
    Q4 2024Quarterly · 2024-12-31ProductBrandedand Other Generic Products69,000,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductDevice Products476,000,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductOther Revenues5,000,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductOverthe Counter Products462,000,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductPharmaceutical Products268,000,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductProduct And Service Other5,000,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31SegmentPharmaceuticals326,000,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31SegmentSurgical231,000,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31SegmentVision Care723,000,000USDLegacy provider
    FY 2024Yearly · 2024-12-31GeographyCanada127,000,000USD0001860742-26-000007
    FY 2024Yearly · 2024-12-31GeographyChina358,000,000USD0001860742-26-000007
    FY 2024Yearly · 2024-12-31GeographyES92,000,000USD0001860742-26-000007
    FY 2024Yearly · 2024-12-31GeographyFrance227,000,000USD0001860742-26-000007
    FY 2024Yearly · 2024-12-31GeographyGermany152,000,000USD0001860742-26-000007
    FY 2024Yearly · 2024-12-31GeographyItaly91,000,000USD0001860742-26-000007
    FY 2024Yearly · 2024-12-31GeographyJapan180,000,000USD0001860742-26-000007
    FY 2024Yearly · 2024-12-31GeographyMX75,000,000USD0001860742-26-000007
    FY 2024Yearly · 2024-12-31GeographyOther Countries712,000,000USD0001860742-26-000007
    FY 2024Yearly · 2024-12-31GeographyPL65,000,000USD0001860742-26-000007
    FY 2024Yearly · 2024-12-31GeographyRU120,000,000USD0001860742-26-000007
    FY 2024Yearly · 2024-12-31GeographySouth Korea47,000,000USD0001860742-26-000007
    FY 2024Yearly · 2024-12-31GeographyUnited Kingdom132,000,000USD0001860742-26-000007
    FY 2024Yearly · 2024-12-31GeographyUnited Statesand Puerto Rico2,413,000,000USD0001860742-26-000007

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.